Treatment of high-risk relapsed acute myeloid leukemia (AML) with haploidentical donor hematopoietic stem cell transplantation based on PTCy regimen

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2000035039

Enrollment

Unknown

Registered

2020-07-29

Start date

2018-01-01

Completion date

Unknown

Last updated

2020-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute myelogenous leukemia

Interventions

Bu+Cy+ATG group:Bu+Cy+ATG

PTCy group:PTCy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: High risk (HR) AML patients and intermediate risk AML patients have suitable donors in CR1 state

Exclusion criteria

Exclusion criteria: Before transplantation, the bone marrow of AML patients could not reach CR state, and there were serious complications of other organs before transplantation, such as severe pulmonary infection, heart failure, liver and kidney dysfunction, etc.

Design outcomes

Primary

Measure	Time frame
event-free survival, EFS;overall survival, OS;transplant related mortality, TRM;relapse rate, RR;HLA match;The number of CD34 cells ;The number of mononuclear cells;the incidence of implation;chimerism;GVHD;Posttransplant lymphoproliferative disorders, PTLD;Genetic test;	—

Secondary

Measure	Time frame
Pathogens associated with Posttransplant infection;DLI;The bridge therapy of desitabine;The cause of death;	—

Countries

China

Contacts

Public ContactJiang Hua

Guangzhou Women and Children's Medical Center

jiang_hua18@sina.cn+86 13533330985

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026